EP2849789A4 - Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren - Google Patents
Zusammensetzungen und verfahren zur diagnose und behandlung von tumorenInfo
- Publication number
- EP2849789A4 EP2849789A4 EP13791411.5A EP13791411A EP2849789A4 EP 2849789 A4 EP2849789 A4 EP 2849789A4 EP 13791411 A EP13791411 A EP 13791411A EP 2849789 A4 EP2849789 A4 EP 2849789A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- tumor
- diagnosis
- compositions
- treatment
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- Optics & Photonics (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261646803P | 2012-05-14 | 2012-05-14 | |
US201361776603P | 2013-03-11 | 2013-03-11 | |
PCT/US2013/031547 WO2013172961A1 (en) | 2012-05-14 | 2013-03-14 | Compositions and methods for the diagnosis and treatment of tumor |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2849789A1 EP2849789A1 (de) | 2015-03-25 |
EP2849789A4 true EP2849789A4 (de) | 2016-02-24 |
Family
ID=49584135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13791411.5A Withdrawn EP2849789A4 (de) | 2012-05-14 | 2013-03-14 | Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren |
Country Status (11)
Country | Link |
---|---|
US (1) | US9580514B2 (de) |
EP (1) | EP2849789A4 (de) |
JP (1) | JP2015523852A (de) |
KR (1) | KR20150013277A (de) |
CN (1) | CN104284677A (de) |
BR (1) | BR112014027905A2 (de) |
CA (1) | CA2871116A1 (de) |
HK (1) | HK1201045A1 (de) |
MX (1) | MX2014013806A (de) |
RU (1) | RU2014145633A (de) |
WO (1) | WO2013172961A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2012245260B2 (en) | 2011-04-22 | 2016-09-08 | Aptevo Research And Development Llc | Prostate-specific membrane antigen binding proteins and related compositions and methods |
US9758591B2 (en) | 2012-08-24 | 2017-09-12 | The Regents Of The University Of California | Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis |
KR20180053322A (ko) | 2015-09-21 | 2018-05-21 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Cd3 결합 폴리펩타이드 |
BR112018067458A2 (pt) | 2016-03-04 | 2019-01-02 | Abmuno Therapeutics Llc | anticorpos para tigit |
KR20240113990A (ko) | 2016-06-27 | 2024-07-23 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
US11690919B2 (en) * | 2017-01-17 | 2023-07-04 | The Texas A&M University System | Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells |
CN113336830B (zh) * | 2017-03-17 | 2023-07-07 | 浙江孚诺医药股份有限公司 | 肿瘤靶向多肽、制备方法及其应用 |
CN109709340B (zh) * | 2018-12-29 | 2022-02-11 | 江苏众红生物工程创药研究院有限公司 | 人中性粒细胞明胶酶相关脂质运载蛋白定量检测卡及其临床应用 |
CA3176246A1 (en) | 2020-06-02 | 2021-12-09 | Arcus Biosciences, Inc. | Antibodies to tigit |
CN112457406B (zh) * | 2020-11-27 | 2022-05-31 | 中国科学院上海药物研究所 | 一种抗mmae的单克隆抗体、其编码序列及应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024392A2 (en) * | 2001-09-18 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP1941909A1 (de) * | 2005-10-24 | 2008-07-09 | Takeda Pharmaceutical Company Limited | Vorbeugungsmassnahmen/heilmittel für krebs |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6037454A (en) * | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
WO2000047713A2 (en) * | 1999-02-09 | 2000-08-17 | Arch Development Corporation | Genes encoding the 5h7 antibody and methods for conferring programmed cell death properties to cells |
US20050272120A1 (en) | 2001-06-20 | 2005-12-08 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CA2633171C (en) * | 2001-06-20 | 2012-11-20 | Genentech, Inc. | Antibodies against tumor-associated antigenic target (tat) polypeptides |
WO2003080856A2 (en) * | 2002-03-19 | 2003-10-02 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
DK1565490T3 (da) * | 2002-11-26 | 2010-08-23 | Axis Shield Asa | Holo-transcobalamin bindingspartnere og deres anvendelse i cobalamintest |
SI2489364T1 (sl) | 2003-11-06 | 2015-04-30 | Seattle Genetics, Inc. | Monometilvalinske spojine, konjugirane s protitelesi |
CA2604377A1 (en) * | 2005-04-08 | 2006-10-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2008085551A2 (en) * | 2006-08-23 | 2008-07-17 | Quercegen Pharma Llc | Smallpox monoclonal antibody |
WO2008029123A1 (en) * | 2006-09-07 | 2008-03-13 | Astrazeneca Ab | Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase |
US20100036091A1 (en) | 2006-11-10 | 2010-02-11 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
US8163279B2 (en) * | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
AU2008272330A1 (en) * | 2007-07-04 | 2009-01-08 | Forerunner Pharma Research Co., Ltd. | Anti-Muc17 antibody |
US8183346B2 (en) * | 2008-12-05 | 2012-05-22 | Eli Lilly And Company | Anti-ferroportin 1 monoclonal antibodies and uses thereof |
PA8849601A1 (es) | 2008-12-05 | 2010-07-27 | Lilly Co Eli | Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos |
CN102459335B (zh) * | 2009-04-17 | 2015-11-25 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
WO2011047146A2 (en) * | 2009-10-14 | 2011-04-21 | Centocor Ortho Biotech Inc. | Methods of affinity maturing antibodies |
US8987423B2 (en) * | 2010-07-22 | 2015-03-24 | Glaxosmithkline Biologicals, S.A. | MAGE antigen binding proteins |
CN103298489A (zh) * | 2010-10-29 | 2013-09-11 | 伊缪诺金公司 | 新型egfr结合分子及其免疫偶联物 |
-
2013
- 2013-03-14 EP EP13791411.5A patent/EP2849789A4/de not_active Withdrawn
- 2013-03-14 CA CA2871116A patent/CA2871116A1/en not_active Abandoned
- 2013-03-14 WO PCT/US2013/031547 patent/WO2013172961A1/en active Application Filing
- 2013-03-14 BR BR112014027905A patent/BR112014027905A2/pt unknown
- 2013-03-14 US US14/400,684 patent/US9580514B2/en not_active Expired - Fee Related
- 2013-03-14 KR KR1020147034670A patent/KR20150013277A/ko not_active Application Discontinuation
- 2013-03-14 RU RU2014145633A patent/RU2014145633A/ru not_active Application Discontinuation
- 2013-03-14 MX MX2014013806A patent/MX2014013806A/es unknown
- 2013-03-14 JP JP2015512643A patent/JP2015523852A/ja active Pending
- 2013-03-14 CN CN201380025032.0A patent/CN104284677A/zh active Pending
-
2015
- 2015-02-12 HK HK15101546.0A patent/HK1201045A1/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024392A2 (en) * | 2001-09-18 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
EP1941909A1 (de) * | 2005-10-24 | 2008-07-09 | Takeda Pharmaceutical Company Limited | Vorbeugungsmassnahmen/heilmittel für krebs |
Non-Patent Citations (5)
Title |
---|
LE HIR H ET AL: "Relative expression of the RET9 and RET51 isoforms in human pheochromocytomas.", ONCOLOGY MAY 2000, vol. 58, no. 4, May 2000 (2000-05-01), pages 311 - 318, XP008178431, ISSN: 0030-2414 * |
M. MUZZA ET AL: "Four novel RET germline variants in exons 8 and 11 display an oncogenic potential in vitro", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 162, no. 4, 26 January 2010 (2010-01-26), GB, pages 771 - 777, XP055235444, ISSN: 0804-4643, DOI: 10.1530/EJE-09-0929 * |
S. ESSEGHIR ET AL: "A Role for Glial Cell Derived Neurotrophic Factor Induced Expression by Inflammatory Cytokines and RET/GFR 1 Receptor Up-regulation in Breast Cancer", CANCER RESEARCH, vol. 67, no. 24, 15 December 2007 (2007-12-15), pages 11732 - 11741, XP055021658, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-07-2343 * |
See also references of WO2013172961A1 * |
SKINNER MICHAEL A ET AL: "RET activation inhibits doxorubicin-induced apoptosis in SK-N-MC cells.", ANTICANCER RESEARCH 2008 JUL-AUG, vol. 28, no. 4B, July 2008 (2008-07-01), pages 2019 - 2025, XP055235442, ISSN: 0250-7005 * |
Also Published As
Publication number | Publication date |
---|---|
US20150098946A1 (en) | 2015-04-09 |
BR112014027905A2 (pt) | 2017-06-27 |
CN104284677A (zh) | 2015-01-14 |
RU2014145633A (ru) | 2016-07-10 |
MX2014013806A (es) | 2014-11-26 |
KR20150013277A (ko) | 2015-02-04 |
HK1201045A1 (en) | 2015-08-21 |
JP2015523852A (ja) | 2015-08-20 |
CA2871116A1 (en) | 2013-11-21 |
WO2013172961A1 (en) | 2013-11-21 |
US9580514B2 (en) | 2017-02-28 |
EP2849789A1 (de) | 2015-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL266582A (en) | Preparations and methods for the treatment of hemoglobin diseases | |
HK1199099A1 (en) | Methods and compositions for the treatment and diagnosis of cancer | |
HK1209788A1 (en) | Methods and compositions for the treatment of lysosomal storage diseases | |
HK1199100A1 (en) | Methods and compositions for the treatment and diagnosis of colorectal cancer | |
HK1200739A1 (en) | Diagnostic methods and compositions for treatment of cancer | |
EP2890815A4 (de) | Verfahren zur diagnose und behandlung von krebs | |
HK1178074A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP2723924A4 (de) | Verfahren und zusammensetzungen zur behandlung und diagnose von krebs | |
HK1202313A1 (en) | Methods and compositions for the treatment and diagnosis of bladder cancer | |
IL238177A0 (en) | Methods and preparations for the treatment of cancer | |
EP2688594A4 (de) | Verfahren und zusammensetzungen zur krebsbehandlung | |
HK1199290A1 (en) | Methods and compositions for the treatment and diagnosis of breast cancer | |
HK1201045A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
HK1197276A1 (en) | Methods and compositions for the treatment and diagnosis of bladder cancer | |
ZA201408056B (en) | Compositions and methods for the treatment of mucositis | |
IL239374B (en) | Preparations and methods for treating brain tumors | |
ZA201408055B (en) | Compositions and methods for the treatment of local pain | |
ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
HK1216721A1 (zh) | 治療肝臟疾病或病狀的用途和方法 | |
EP2928456A4 (de) | Verfahren und zusammensetzungen für die behandlung von krebs | |
ZA201408065B (en) | Compositions and methods for the treatment of diabetes | |
ZA201408058B (en) | Compositions and methods for the treatment of epilepsy | |
PL2855475T3 (pl) | Alfa-karboliny do leczenia nowotworu | |
GB201213486D0 (en) | Quinone compounds and their uses for the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20141215 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SHANG, YONGLEI Inventor name: JUNUTULA, JAGATH R. Inventor name: HONGO, JO-ANNE S. Inventor name: HAZEN, MEREDITH Inventor name: BHAKTA, SUNIL Inventor name: HOTZEL, ISIDRO Inventor name: YU, SHANG-FAN |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/48 20060101ALI20160113BHEP Ipc: C12Q 1/68 20060101ALI20160113BHEP Ipc: C07K 16/30 20060101ALI20160113BHEP Ipc: A61K 39/395 20060101AFI20160113BHEP Ipc: A61K 51/10 20060101ALI20160113BHEP Ipc: G01N 33/574 20060101ALI20160113BHEP Ipc: A61K 39/00 20060101ALI20160113BHEP |
|
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20160121 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 39/395 20060101AFI20160115BHEP Ipc: G01N 33/574 20060101ALI20160115BHEP Ipc: C07K 16/30 20060101ALI20160115BHEP Ipc: A61K 47/48 20060101ALI20160115BHEP Ipc: A61K 39/00 20060101ALI20160115BHEP Ipc: A61K 51/10 20060101ALI20160115BHEP Ipc: C12Q 1/68 20060101ALI20160115BHEP |
|
17Q | First examination report despatched |
Effective date: 20170209 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170420 |